New drug IEV407 takes on advanced breast cancer in early trial

NCT ID NCT07604571

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 2 times

Summary

This early-phase study tests a new drug called IEV407, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer that has stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 194 participants will take part across multiple centers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED HR+/HER2- BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED HR+/HER2- BREAST CANCER

Contacts and locations

Locations

Mary Crowley Cancer Research
RECRUITING

Dallas, Texas, 75251, United States
Novartis Investigative Site
RECRUITING

Hirakata, Osaka, 5731191, Japan
Novartis Investigative Site
RECRUITING

Singapore, 119074, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.